Home > For doctors > Protocols> Psychiatry

Search

Depression

Mnemonic for depression diagnosis

Sheffield adult depression guideline or Sheffield adult depression guideline

Microsoft Word document General health questionnaire (GHQ)

The MacArthur Initiative on Depression Primary Care

 

Mastering depression in primary care


The Importance of Depression

Why should Depression be treated in Primary Care?

Diagnosis

The term depression describes a continuum from a normal lowering of mood that affects everyone from time to time, to a severe disorder. In general practice, we are generally talking about major depression, which can be classified as mild, moderate and severe.

Other forms of depression are also important and include:

Core symptoms of depression

The presence of at least two of:
  • Depressed mood and/or
  • loss of interest and pleasure and/or
  • loss of energy and fatigue.
Plus some of the following:
  • feelings of worthlessness or guilt;
  • reduced concentration and/or attention;
  • bleak and pessimistic views of the future;
  • thoughts or acts of self harm/suicide;
  • loss or increase of appetite and weight;
  • insomnia or hypersomnia;
  • retardation or agitation;
  • reduced self-esteem and/or confidence.

However, if important symptoms such as agitation or retardation are marked, patients may be unwilling or unable to describe some symptoms in detail. The symptoms should have been present for at least two weeks unless they are particularly severe and of very rapid onset.

Severity of depression

Mild Depression
  • At least two of the first three symptoms, plus at least two of the other symptoms.
  • Symptoms should not be present to an intense degree.
  • The individual is usually distressed by the symptoms and has some difficulty continuing with work and social activities but will probably not cease to function completely.
Moderate Depression
  • At least two of the first three symptoms, plus at least three (preferably four) of the other symptoms.
  • Several symptoms are likely to be present to a marked degree.
  • There will be considerable difficulty continuing with work etc.
Severe Depression
  • The sufferer usually shows considerable distress or agitation or retardation.
  • Loss of self-esteem or feelings of uselessness and guilt are likely to be prominent.
  • It is unlikely that the sufferer would be able to continue with social, work or domestic activities, except to a limited extent.

Differential diagnosis

Symptoms of anxiety or nervousness are frequently present along with depressive symptoms. Where depression is significant (as defined above), treat the depression. Specific counselling and advice about self-help may address symptoms of both anxiety and depression.

Recognition of Depression

Which groups are high risk?

Less obvious ways in which depression may present

Note: Patients with learning disabilities can suffer from depression and may present with agitation/aggression, irritability, reduction in self care, reduction in quantity of speech. Refer for specialist advice.

Recognition in more complex cases

If these situations co-exist with depression, the depression may be missed or may be attributed exclusively to the situation. Where depression is significant, it should be treated, regardless of whether it seems understandable in the circumstances.

Screening tests

The use of screening tests increases the recognition of depression in general practice. A number of self administered rating scales are available for patients to fill in. These save on staff time and improve accuracy of diagnosis. It is also useful to repeat the screening tests at intervals through treatment as an assessment of progress. The five most commonly used scales are:

How can a practitioner improve his or her recognition skills?

The therapeutic effect of a medical consultation has been widely accepted following the work of Balint. There may be similar opportunities for a therapeutic consultation effect from a nurse.

Acute Management of Depression

Assess suicide risk

Possible questions to ask are:

Distinguish between just thoughts and actual intentions, actual plans and previous attempts.

If the patient has no ideas, intentions, plans or previous attempts, then treat depression. If the patient has ideas and vaguely phrased intentions but no definite plans or history, then treat depression and monitor closely. Involve family or carer in monitoring if possible. If the patient has thoughts plus definite intentions, actual plans or previous history, consult specialist.

Other factors associated with suicide risk:

Assess severity of the depression and develop action plan

Mild Depression

Moderate to Severe Depression

Where depression is prolonged or relapse frequent, consider referral for cognitive behavioural therapy and/or problem solving treatment.

Where depression is prolonged or relapses are frequent and it is clear that particular psycho-social issues are relevant - consider referral to a counsellor trained in helping with the particular issues identified.

In addition to addressing social and contextual issues, consider prescribing antidepressants:

Severe depression is unlikely to respond to talking therapies and self help strategies until sufficiently improved with drug treatment. Once sufficiently improved, treat as for moderate to severe.

Explain to the patient how the medication should be used:

Essential information about depression for the patient and their family

They need to be aware and comfortable with the idea that:

Specific counselling for the patient and their family

Where significant symptoms of anxiety are also present

Continuing Management of Depression

Factors which may predict an incomplete response

Relapse prevention

Recurrent depression

This is defined as three episodes of severe depression in five years.

Consult specialist when ......

Treatment

As with most psychiatric conditions depression is generally complicated by having a multi-factorial aetiology with a wide range of variables influencing vulnerability, onset, clinical picture course and prognosis; this is reflected in the range of therapeutic interventions which may need to be considered.

Treatment options broadly fall under the following headings:

This guidance concentrates on the use of medication, but it should be borne in mind that support from any clinical practitioner may be crucially important. Of the psychotherapeutic interventions that have been studied in depression, cognitive therapy has consistently been shown to be the most effective and whilst this may not be used routinely, a referral for assessment should be considered in patients who do not respond to medication and simpler treatments.

Effective treatment depends on accurate diagnosis; the practitioner must first distinguish clinical depression, (sufficiently severe and disabling to require intervention) from sadness or distress which is part of normal life experience. Good response to treatment with antidepressants is seen in patients with more than mild symptoms: Studies have shown that where there are only few or very mild depressive symptoms the evidence of response to drugs is questionable and effort should therefore be concentrated on prescribing for those with more clearly established depressive illness.

It is helpful to think of treatment in three phases:

Once selected, the initial treatment should be provided for a sufficient length of time to permit a reasonable assessment of response (or lack of it). With medication this means a minimum of four to six weeks.

The selection of the initial and subsequent treatments should be a collaborative decision between the practitioner and patient; nevertheless, if the patient shows a partial response to treatment by four to six weeks it is generally reasonable to continue it unchanged for a further similar period. If, however, the patient has not responded at all by six weeks or only partially responds by ten to twelve weeks, other treatment options should be considered. Antidepressants are effective in depressive disorders satisfying the criteria for major depressive episodes and in episodes a little below this threshold, but they have not been found to be effective in the very mild end of the depression range.

They may be effective in the presence of life-stress and should not be withheld purely because the depression seems understandable.

A wide choice of antidepressant compounds is available, all of which have advantages and disadvantages. The advantages of the older tricyclic antidepressants are that they are cheap and have a well-known side effect profile. The newer SSRIs are less toxic in overdose and exhibit a different range of side effects.

It is considered reasonable, in a physically healthy patient who is not at high risk of suicide (particularly overdosing) and without vulnerability to cardiotoxic or anticholinergic side effects, to begin treatment with a tricyclic antidepressant. The dose may be started at 75 mg daily of Amitriptyline or equivalent, although it should be recognised that this is likely to be sub-therapeutic. The dose should be increased quite quickly (depending on side effects) to 125 to 150 mg daily which is the recommended treatment dose. The elderly do require smaller doses and a slower dose titration.

Where agitation is prominent it is reasonable to use a more sedative antidepressant such as Amitriptyline or Dothiepin; indeed, such drugs may be useful in some patients where initial insomnia is a significant problem. If, for any reason, these drugs are not used or are ineffective it is reasonable to use another mildly sedative agent such as Thioridazine (in relatively low dose, say 25 mg two or three times a day) for a period until symptoms begin to subside. Benzodiazepines should only be used where anxiety and/or agitation are severe and only then in short courses for a maximum of two weeks; Diazepam would then be the drug of choice with a starting dose of no higher than 10-20mg per day.

If the patient does not respond to an adequate trial (as previously described) then other treatment options may need to be considered. Likewise if a patient is unable to tolerate tricyclic antidepressants, is at risk of overdose or if toxicity is likely to be a problem then appropriate drugs to consider "second line" are serotonin specific re-uptake inhibitors such as fluoxetine, paroxetine, sertraline and citalopram. If these drugs have been used "first line" and have not been tolerated or have proved ineffective, it may be worth (if possible) proceeding to a tricyclic. Lofepramine, whilst being a tricyclic, has fewer problems of side effects and toxicity than many of the older drugs. Lofepramine appears similar in efficacy and tolerability to alternative antidepressants.

If tricyclics or SSRIs have not been effective, the group of drugs often used "third line" are the Monoamine Oxidase Inhibitors. The most commonly prescribed drug in this group is phenelzine and, although these agents entail dietary restrictions and carry greater risks of drug interactions (particularly sympathomimetic), they are effective antidepressants, particularly when phobic, atypical, hypochondriacal or hysterical features are present.

MAOIs, other than moclobemide, have considerable side effects and are unlikely to be appropriate for initiation in general practice. Moclobemide, however, is less prone to dangerous side effects and appears to have similar tolerability and efficacy to other available antidepressants. They should be tried in any patients who are refractory to treatment with other antidepressants as there is sometimes a marked response, but if such drugs are being contemplated it would generally be appropriate to discuss the patient with a consultant psychiatrist or make a referral. MAOIs should not be started until two weeks after an SSRI has been stopped (5 weeks for fluoxetine.)

Most treatment options beyond this stage should generally be undertaken by specialist. teams and frequently the next step beyond MAOIs is combination treatment by augmentation with Lithium; combinations of Lithium and tricyclics and Lithium and MAOIs are used and some clinicians favour a combination of a tricyclic and an SSRI in certain circumstances. Literature does contain some studies involving the combination of tricyclic and MAOI drugs, but this should never be prescribed in general practice as there are considerable dangers.

Electroconvulsive therapy, certain anticonvulsants and thyroid hormone are all sometimes used in certain cases which are treatment resistant, but should only usually be initiated with reference to specialist psychiatric teams.

Antidepressant drugs should not be used in isolation in treatment; the aims and intentions of treatment should be made clear to the patient, as should the mechanisms of action and side effects of the drugs. Evidence suggests that patients' lack of knowledge plays a significant part in higher rates at which drug therapy gets abandoned and they should always be warned that initial treatment response is likely to be delayed by two to three weeks.

Continuation treatment should be undertaken for a period of between four and six months after the acute treatment phase and the dose of drug should be continued at or near the initial therapeutic level. Beyond this, decisions about longer-term prophyllaxis should be based on the likelihood of further recurrent episodes and discussion with the patient over the risks and benefits. The total duration of prophyllaxis in those with relapse or recurrence remains a matter of clinical judgement depending on the individual circumstances.

Recommendations

Antidepressants: relative adverse effects

Drug

Trade name

Sedation

Cardiovascular effects

Anti-Cholinergic Effects

Forms available

Tricyclics (in order of introduction)
Imipramine Tofranil ++ +++ +++ tabs, liq
Amitriptyline Tryptizol +++ +++ +++ tabs/caps, liq, inj
Desipramine Pertofran + ++ ++ tabs
Nortriptyline Aventyl + ++ ++ tabs
Trimipramine Surmontil +++ +++ ++ tabs, caps
Doxepin Sinequan +++ ++ ++ caps
Dothiepin Prothiaden +++ +++ ++ tabs, caps
Clomipramine Anafranil ++ +++ ++ tabs/caps, liq, inj
Lofepramine Gamanil + + + tabs
Atypical Antidepressants (In Order of Introduction)
Trazodone Molipaxin +++ + - caps, liq
Venlafaxine Efexor ++ + + tabs
Nefazodone Dutonin ++ + + tabs
Reboxetine Edronax + + ++ tabs
Selective Serotonin Reuptake Inhibitors (SSRIs)
Citalopram Cipramil - - - tabs
Fluvoxamine Faverin + - - tabs
Fluoxetine Prozac - - - caps, liq
Sertraline Lustral - - - tabs
Paroxetine Seroxat + - + tabs
Monoamine Oxidase Inhibitors (MAOIs)
Isocarboxazid Maarplan + ++ ++ tabs
Phenelzine Nardil + + + tabs
Tranylcypromine Parnate - + + tabs

Reversible Inhibitor of Monoamine Oxidase A (RIMA)

Moclobemide Manerix - - - tabs

 

Management tools

Once a diagnosis of depression is made, severity can be measured by

Mild
  • HADS score 8 to 10
  • Beck score = 14 to 19 and/or
  • at least from two from the key symptoms plus two others.

None of symptoms present to an intense degree, still functioning reasonably well, although with difficulty.

There is no evidence that medication is helpful for this group. Acknowledge, reassure and see again. Give suitable self help literature and advice on sleep,diet etc. Use of problem solving approach/relaxation/give self help. Assess social difficulties. give information on where to find help. Use of GP /nurse counselling skills.
Moderate
  • HADS score 11 to 14
  • Beck score = 20 to 28 and/or
  • at least two from the key symptoms plus three or four others.

Present to a marked degree or a particularly wide range or symptoms.

All steps as previous plus regular follow up. Medication to be built up to correct therapeutic dose and given for 4-6 months, with guidelines and/or offer/refer to counselling/cognitive therapy .
Severe
  • HADS score 15 to 21
  • Beck score = 29 or above and/or
  • mostsymptoms, present in a severe form.

Great difficulty on continuing to function occupationally and socially.

All steps as previous - but see frequently. Consider seeing carers/family. Consider referrral to specialist.

Making it happen - a summary

• Maintain a high index of suspicion, especially with high risk groups. • Ensure good communication amongst Primary Care Health Teams (PHCT) and with the Community Mental Health Team. • Ensure continuity of care and invite the patient back for regular review. • Use guidelines and have a strategy for relapse prevention. • Provide a patient library with self help literature or encourage patients to acquire this type of information from libraries or bookshops. • Plan training and support for staff. • Consider audit - Consult Medical Audit Advisory Group (MAAG). • Add a mental health element to new patient and other physical screening programmes.


References

  1. NFER-Nelson, Darville House, 2 Oxford Road East, Windsor, Berks, SL4 1BU. (General Health Questionnaire and Hospital and Anxiety Depression Scale, available as individual packs of questionnaires or as part of a comprehensive mental health assessment portfolio).
  2. Recognition and Management of Depression in Late Life in General Practice: Consensus Statement. Katona C, Freeling P, Hinchcliffe R, Blanchard M and Weight A (1995). Primary Care Psychiatry, Volume 1, p107-113.
  3. Perinatal Psychiatry. Use and Misuse of The Edinburgh Postnatal Depression Scale. Cox and Holden (1994). Gaskell London.
  4. Psychological Corporation, Foots Cray High Street, Sidcup, Kent, DA14 5HP. (0181-3085750).
  5. Suicide Risk: A Guide for Primary Care Teams and Mental Health Staff. MacDonald F, Northumberland Mental Health Trust.
  6. Drug Treatment of Depression. Guidelines for General Practitioners in Northumberland. Northumberland Health Authority, September 1998.

Source: Northumberland Mental Health NHS Trust guidelines 1998 and 1999 and Northamptonshire Health Authority Defeat Depression guidelines.


 
D = Depressed mood

E = Energy loss/fatigue

P = Pleasure lost

R = Retardation or excitation

E = Eating changed—appetite/weight

S = Sleep changed

S = Suicidal thoughts

I = I'm a failure (loss of confidence)

O = Only me to blame (guilt)

N = No concentration